News RepliCel Life Sciences Inc. Toronto S.E.

Equities

RP

CA76027P4006

Delayed Toronto S.E. Other stock markets 08:30:00 16/04/2024 pm IST			5-day change	1st Jan Change
0.055 ^CAD	-.--%		-21.43%	-15.38%

31/05	RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
17/05	RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	31/05	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/05	CI
Canadian Investment Regulatory Organization Trading Halt - RP	08/05	AQ
RepliCel Life Sciences : Announces Secured Loan Agreement	19/04	PU
RepliCel Life Sciences Inc. Announces Secured Loan Agreement	18/04	CI
RepliCel Life Sciences : announces a Letter of Intent for Asset Purchase Agreement - Form 6-K	21/03	PU
RepliCel Life Sciences : Letter of Intention (Asset Purchase)	18/03	PU
Canadian Investment Regulatory Organization Trading Halt - RP	15/03	AQ
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	30/11	PU
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11	CI
RepliCel Life Sciences : Arbitration decision	17/11	PU
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	24/23/24	PU
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/23/24	CI
RepliCel Life Sciences : AGM 2023 Zoom Link and Materials	22/23/22	PU
Replicel Life Sciences Inc. Announces That Peter Lowry Will Not Be Standing for Re-Election as A Director	31/23/31	CI
RepliCel Life Sciences : Notice of Meeting and Record Date - Form 6-K	17/23/17	PU
RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors	17/23/17	CI
RepliCel Life Sciences Inc. Announces Chief Financial Officer Changes	17/23/17	CI
REPLICEL LIFE SCIENCES : STATEMENT OF EXECUTIVE COMPENSATION - Form 6-K	10/23/10	PU
RepliCel Life Sciences : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	31/23/31	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News RepliCel Life Sciences Inc. Toronto S.E.

Equities

RP

CA76027P4006

Summary

Filters